(Q37834648)

24 August 2017

1 reference

title

Parkinson's disease--the continuing search for biomarkers (English)

1 reference

24 August 2017

0 references

1 reference

3

Roger A Barker

1 reference

24 August 2017

David P Breen

1

1 reference

24 August 2017

Andrew W Michell

series ordinal

2

1 reference

24 August 2017

publication date

3 February 2011

1 reference

Clinical Chemistry and Laboratory Medicine

24 August 2017

published in

1 reference

24 August 2017

volume

49

1 reference

24 August 2017

issue

3

1 reference

24 August 2017

page(s)

393-401

1 reference

Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Evolution of cognitive dysfunction in an incident Parkinson's disease cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Practice Parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Ageing and Parkinson's disease: substantia nigra regional selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

An [18F]dopa-PET and clinical study of the rate of progression in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The heterogeneity of idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Designing neuroprotection trials in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Phosphorus and proton magnetic resonance spectroscopy demonstrates mitochondrial dysfunction in early and advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Mitochondria in the aetiology and pathogenesis of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Microglial activation and dopamine terminal loss in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Alpha-synuclein in Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NO(x) content in the CSF. A different marker profile in four neurodegenerative diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Soluble oligomers for the diagnosis of neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Autosomal-dominant locus for Restless Legs Syndrome in French-Canadians on chromosome 16p12.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Osteopontin is elevated in Parkinson's disease and its absence leads to reduced neurodegeneration in the MPTP model

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Tissue transglutaminase-induced aggregation of alpha-synuclein: Implications for Lewy body formation in Parkinson's disease and dementia with Lewy bodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

CSF neurofilament light chain and tau differentiate multiple system atrophy from Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Memory and executive function impairment predict dementia in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Dementia and survival in Parkinson disease: a 12-year population study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

CSF amyloid-beta and tau proteins, and cognitive performance, in early and untreated Parkinson's disease: the Norwegian ParkWest study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Cerebrospinal tau, phospho-tau, and beta-amyloid and neuropsychological functions in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Dynamic changes of anandamide in the cerebrospinal fluid of Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Parkinson patient fibroblasts show increased alpha-synuclein expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Increased serum levels of soluble tumor necrosis factor-alpha receptor-1 in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Oxidative damage in Parkinson disease: Measurement using accurate biomarkers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Lower serum ceruloplasmin levels correlate with younger age of onset in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Abnormal serum concentrations of proteins in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Metabolomic profiling to develop blood biomarkers for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Serum urate as a predictor of clinical and radiographic progression in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

High-resolution diffusion tensor imaging in the substantia nigra of de novo Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Cortical dysfunction in non-demented Parkinson's disease patients: a combined (31)P-MRS and (18)FDG-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Endpoints and analyses to discern disease-modifying drug effects in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

The delayed-start study design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction?

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Saccadic latency distributions in Parkinson's disease and the effects of L-dopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Predictors and course of health-related quality of life in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson's disease left untreated at diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Progression of Parkinson's disease in the clinical phase: potential markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Placebo response in Parkinson's disease: comparisons among 11 trials covering medical and surgical interventions

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

Biomarkers in Huntington's and Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

UPDRS activity of daily living score as a marker of Parkinson's disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2011.080

21 January 2018

Identifiers

DOI

10.1515/CCLM.2011.080

1 reference

24 August 2017

1 reference